Cutaneous T-Cell Lymphoma/Mycosis Fungoides Clinical Trial
Official title:
Pilot Study of HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
Participants will be randomized to receive HyBryte or Valchlor in a 1:1 randomization. Participants will be treated for 12 weeks and follow-up visits will be conducted 1, 2, and 4 weeks after completion of the treatment phase of the trial. Prior to randomization, each participant will have at least 3 and up to 5 lesions identified (index lesions) that will be evaluated during the treatment phase and during the follow-up visits. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03837457 -
PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study
|
Phase 2 | |
| Recruiting |
NCT06436677 -
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
|
||
| Completed |
NCT05380635 -
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT04702503 -
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
|
Phase 1 | |
| Not yet recruiting |
NCT06113081 -
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
|
||
| Terminated |
NCT03713320 -
SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides
|
Phase 2 |